Attovia Therapeutics, Inc., based in San Carlos, California, disclosed on September 3, 2026, that the clinical-stage biopharmaceutical company, known as Attovia (Nasdaq: ATTO), is focusing on developing advanced biotherapeutics for immune-mediated diseases that have a significant lack of effective treatments. The company's management is set to take part in several investor conferences.